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ABSTRACT
We report a robust display technology for the
screening of disulfide-rich peptides, based on
cDNA–protein fusions, by developing a novel and
versatile puromycin-linker DNA. This linker com-
prises four major portions: a ‘ligation site’ for T4
RNA ligase, a ‘biotin site’ for solid-phase handling,
a ‘reverse transcription primer site’ for the efficient
and rapid conversion from an unstable mRNA–
protein fusion (mRNA display) to a stable mRNA/
cDNA–protein fusion (cDNA display) whose cDNA
is covalently linked to its encoded protein and a
‘restriction enzyme site’ for the release of a complex
from the solid support. This enables not only stabi-
lizing mRNA–protein fusions but also promoting
both protein folding and disulfide shuffling reac-
tions. We evaluated the performance of cDNA
display in different model systems and demon-
strated an enrichment efficiency of 20-fold per
selection round. Selection of a 32-residue random
library against interleukin-6 receptor generated
novel peptides containing multiple disulfide bonds
with a unique linkage for its function. The pep-
tides were found to bind with the target in the low
nanomolar range. These results show the suitability
of our method for in vitro selections of disulfide-rich
proteins and other potential applications.
INTRODUCTION
Phage display techniques are powerful tools for selecting
peptides and proteins that bind with high aﬃnity and spe-
ciﬁcity to target molecules from random sequence libraries
(1). Recently, several in vitro display techniques (geno-
type–phenotype linkage technology) have been developed
using cell-free translation systems to overcome the diﬃcul-
ties associated with conventional cellular and phage-based
display methods. The main potential advantage of using
in vitro methods is to generate large libraries and thus
increase the diversity of the proteins being screened by
four or more orders of magnitude compared with phage-
display methods (2).
In recent years, both ribosome display (3,4) and ‘in vitro
virus’ mRNA display (5,6) have already been proved to
be very successful and practical in vitro techniques for
exploring functional peptides and proteins from large
libraries (7). These methods have enabled the binding of
mRNA molecules to their encoded protein products via a
ribosome or a puromycin molecule. Owing to the simple
formation of mRNA–protein fusions in this instance,
these molecules can be applied not only in evolutionary
*To whom correspondence should be addressed. Tel: +81 48 858 3531; Fax: +81 48 858 3531; Email: nemoto@fms.saitama-u.ac.jp
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.molecular engineering studies, but also in genome-wide
proteomics and analyses of protein function (8,9).
However, mRNA-dependent technology has so far been
perceived as technically challenging owing to the labile
nature of RNA molecules. For example, the application
of mRNA display techniques for the analysis of cell sur-
face antigens can be presumably problematic due to ribo-
nuclease activity of the cells. On the other hand, phage
display has proved to be very robust and successful
in the screening of antibody fragments directed against
cell-surface proteins that are important drug targets,
such as G protein-coupled receptors (GPCR) (10,11).
To increase the stability of the mRNA display products
(i.e. mRNA–protein fusion molecules), the labile aspect of
the mRNA region has been improved by the additional
synthesis of its cDNA counterpart and the generation of
an mRNA/cDNA–protein fusion molecule using a puro-
mycin–linker DNA harboring a primer for reverse tran-
scription (RT) (12,13). Although these methods facilitate
ready RT without the addition of primers into the lysate,
it is still necessary to rapidly purify the mRNA–protein
fusion molecules to avoid any further degradation by
nucleases that may have contaminated the cell-free trans-
lation reaction and also to release the ribosome that
remains bound to the coding regions of the mRNAs.
In this article, we report a novel screening method by
using a puromycin-linker DNA containing a ‘ligation
site’, a ‘biotin site’ ‘reverse transcription primer site’ and
a ‘restriction enzyme site’ described in the previous report
(14). These features facilitate extremely rapid ligation of
mRNA and linker, biotin/streptavidin-based puriﬁcation
and cDNA synthesis by RT that together prevent degrada-
tion of mRNA, signiﬁcantly reduce the execution time,
allow conversion of mRNA–protein fusion (mRNA dis-
play) to cDNA–protein fusion (cDNA display), where the
cDNA remains covalently linked to their encoded protein
and facilitates solid-phase handling (Figure 1). Thus, dis-
ulﬁde-rich proteins can also be expressed and refolded by
easy and rapid buﬀer exchange. The cDNA display enables
in vitro selection of various kinds of peptide and protein
libraries of more than 10
12 diﬀerent sequences comparable
to or higher than other in vitro display techniques.
We validated the performance of this novel puromycin–
linker DNA in a screening for test proteins (immunoglo-
bulin G, POU-speciﬁc DNA-binding domain of Oct-1 and
anti-FLAG antibody). Selection against interleukin-6
receptor (IL-6R) using a 32-residue random peptide
library allowed us to identify novel peptides with multiple
disulﬁde bonds that have not been reported by other
methods. We also found and showed that one of the
selected peptides requires a unique disulﬁde linkage for
its function.
MATERIALS AND METHODS
Chemicals and reagents
The modiﬁed oligonucleotides ‘Puro-F-S’ and ‘Biotin-
loop’ were obtained from Geneworld (Tokyo). ‘Puro-
F-S’ stands for 50-(S)-TC(F)-(Spec18)-(Spec18)-(Spec18)-
(Spec18)-CC-(Puro)-30, where (S): 50-Thiol-ModiﬁerC6,
(F): Fluorescein-dT, (Puro): Puromycin CPG and
(Spacer18): Spacer Phosphoramidite 18. ‘Biotin-loop’
stands for 50-CCCGGTGCAGCTGTTTCATC(T-B)CG
GAAACAGCTGCACCCCCCGCCGCCCCCCG(T)CC
T-30, where (T): Amino-Modiﬁer C6 dT, and (T-B):
Biotin-dT (underline indicates a recognition sequence for
the PvuII restriction enzyme). EMCS [N-(6-Maleimidoca-
proyloxy) succinimide] was purchased from Dojindo
(Kumamoto, Japan). TCEP [Tris (2-Carboxyethyl) phos-
phine] was purchased from Pierce.
Vectors, oligonucleotides and library construction
The B domain of protein A (15) was obtained from the
pEZZ 18 protein A gene fusion vector (GE Healthcare).
The primers used were as follows: a forward primer incor-
porating the T7 promoter, the 50 untranslated region
‘omega’ of tobacco mosaic virus (TMV), a Kozak
sequence and an ATG start codon; a reverse primer har-
boring a hexa-histidine tag, a spacer sequence (GGGGGA
GGCAGC) and a complementary sequence (AGGACGG
GGGGCGGGGAAA) for the puromycin–linker DNA
at the 30-terminus to enable ligation between the mRNA
and the puromycin–linker DNA. In the case of the Pou-
speciﬁc DNA-binding domain of Oct-1 (PDO) (16), the
template was generated by replacing the B domain
region with PDO.
For the aﬃnity selection of the anti-FLAG M2 anti-
body, two single-stranded synthetic DNAs (27-mers)
encoding the FLAG epitope and a random decamer pep-
tide were purchased from the FASMAC Corporation
(Japan). The DNA encoding the random decamer peptide
comprised the codon triplets XYZ, where X, Y and Z
indicate nucleotide mixtures, and the mixing ratios were
X: T 13%, C 20%, A 35%, G 32%; Y: T 24%, C 22%, A
30%, G 24%; and Z: T 37%, C 37%, A 0%, G 26% (17).
Similarly, the 35 residues library was prepared by DNAs
encoding the 32 random residues using codon triplets as
mentioned above.
Synthesis of puromycin–linker DNA
The modiﬁed oligonucleotides: ‘Puro-F-S’ and ‘Biotin-
loop’ were obtained from Geneworld (Tokyo) and
BEX (Tokyo). ‘Puro-F-S’ stands for 50-(S)-TC(F)-
(Spec18)-(Spec18)-(Spec18)-(Spec18)-CC-(Puro)-30, where
(S):50-Thiol-Modiﬁer C6, (F): Fluorescein-dT, (Puro):
Puromycin CPG and (Spacer18): Spacer Phosphoramidite
18. ‘Biotin-loop’ stands for 50-CCCGGTGCAGCTGTTT
CATC(T-B)CGGAAACAGCTGCACCCCCCGCCGCC
CCCCG(T)CCT-30, where (T): Amino-Modiﬁer C6 dT
and (T-B): Biotin-dT (underline indicates a recognition
sequence for the PvuII restriction enzyme).
The 50-thiol group of ‘Puro-F-S’ (10 nmol) was reduced
by 1mM TCEP in 100ml of 50mM phosphate buﬀer (pH
7.0) for 6h at room temperature and then desalted on a
NAP-5 column (GE Healthcare) just before use. Total
10nmol of ‘Biotin-loop’ and 2mmol EMCS were then
added to 100ml of 0.2M sodium phosphate buﬀer, pH
7.0. The mixture was subsequently incubated for 30min
at 378C and ethanol precipitation was performed at 48Ct o
remove excess EMCS. The precipitate was washed twice
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10ml of pre-cooled 0.2M sodium phosphate buﬀer (pH
7.0). The reduced ‘Puro-F-S’ was immediately added and
stirred at 48C overnight. The reaction was stopped by
adding 4mM TCEP for 15min at 378C. Ethanol precipi-
tation was then performed to remove the excess ‘Puro-F-S’
at room temperature. To remove the ‘Biotin-loop’ and the
uncrosslinked Biotin-loop–EMCS complexes, the precipi-
tate was dissolved with 0.1M TEAA (Glen Research) or
phosphate buﬀer and puriﬁed with a C18 HPLC column
under the following conditions: column: AR-300,
4.6 250mm (Nacalai Tesque, Japan); solvent A: 0.1M
TEAA; solvent B: acetonitrile/water (80:20, v/v); gradient;
B/A(15–35%, 33min); ﬂow rate: 0.5ml/min; detection by
absorbance at 254nm and 490nm. The fraction from the
last peak at an absorbance of 254nm (corresponding to a
single peak at an absorbance of 490nm) was collected.
After drying, the ‘puromycin–linker DNA’ was resus-
pended in diethylpyrocarbonate (DEPC)-treated water
and stored.
Immobilization of mRNA–puromycin conjugates on
magnetic beads
Streptavidin-coated magnetic beads of 2.3mm in size
(MAGNOTEX-SA, Takara) were washed twice with
binding buﬀer (10mM Tris–HCl pH 8.0, 1mM EDTA,
1M NaCl, 0.1% Triton X-100) according to the manufac-
turer’s instructions. The mRNA–puromycin conjugate (48
pmol) and SA beads (1.2mg) were then incubated in 120ml
of binding buﬀer for 10min at room temperature. The
beads were subsequently washed once each with binding
buﬀer and translation mix buﬀer (Ambion), prior to cell-
free translation.
Cell-free translation and RT on magnetic beads
After separation of the magnetic beads with a magnetic
stand, 300ml of cell-free translation extracts (Ambion)
were added and the mixture was incubated at 308C for
20min. To increase the yield of mRNA–protein fusions,
the post-translation fusion reaction was performed for an
additional incubation of translated product at 378C for
90min in the presence of high-salt concentrations (KCl
and MgCl2 to ﬁnal concentrations of 750 and 63mM,
respectively). The beads bounded with the expressed
mRNA–protein complex were then washed twice with
200ml of binding buﬀer containing RNase inhibitor
(SUPERaseIn, Ambion) and rinsed with 100mlo fR T
buﬀer (50mM Tris–HCl pH 8.3, 75mM KCl, 3mM
MgCl2). RT was performed at 428C for 10min by
adding 80ml of RT buﬀer and 80 units of reverse tran-
scriptase M-MLV (Takara) to the beads.
Refolding of disulfide-rich proteins
The cDNA–protein fusions on streptavidin-coated
magnetic beads were reduced by the addition of 100mM
DTT for 1h at 258C and washed with binding buﬀer
(Takara). Refolding was performed in the presence
of 1mM oxidized glutathione, 10mM reduced gluta-
thione and protein disulﬁde isomerase at an equimolar
ratio with the input cDNA fusions for 1h at 258C.
The beads were washed and subjected to PvuII digestion
(mentioned below) and Ni–NTA puriﬁcation followed by
selection.
Collection of cDNA–protein fusion molecules from
magnetic beads
The magnetic beads bounded with the reverse transcribed
mRNA–protein fusions were washed once with binding
buﬀer followed by ‘M buﬀer’ (10mM Tris–HCl pH 7.5,
10mM MgCl2, 1mM DTT, 50mM NaCl; TaKaRa) and
separated using a magnetic stand. The release of the
mRNA/cDNA–protein fusion molecules from the beads
was performed at 378C for 1h by the addition of M
buﬀer (40ml) and 24 units of PvuII (Takara) and BSA
(ﬁnal concentration 0.1mg/ml). BSA was added to
reduce any non-speciﬁc interactions between the mRNA/
cDNA–protein fusion products and the beads. The
cDNA–protein fusion products were then puriﬁed from
the remaining supernatant using Ni–NTA agarose beads
(QIAGEN).
For detection, after separation of the beads from this
reaction, the supernatant was transferred to a new tube
and mRNA was removed by incubation with 2 units
of ribonuclease H (Promega) at 378C for 20min and sub-
jected to SDS–PAGE containing 6M urea. Fluoroimager
(Typhoon 8600) was then used to view and quantify the
bands on the gel by the detection of the FITC label
attached to the puromycin–linker.
Protein immobilization and labeling
Immunoglobulin G (IgG; Sigma), IL-6R (Peprotech) and
bovine serum albumin (BSA; Ambion) (50mg) were
coupled to 200ml of NHS-activated Sepharose 4 Fast
Flow (GE Healthcare) according to manufacturer’s
instructions. The ﬁnal solution was prepared as 50%
slurry. Non-coated beads were also prepared by the
same method in the absence of protein.
The double-stranded DNA harboring the Pou binding
site was prepared by the hybridization of the oligonucleo-
tides 50-CCAGGGTATGCAAATTATTAAGGGCAAA
AA-biotin-30 and 50-TTTTTGCCCTTAATAATTTGCA
TACCCTGG-30. The underlined sequences indicate the
Pou binding site (16). The resulting biotinylated dsDNA
(hereby referred to as Oct-DNA) was then immobilized on
streptavidin-coated sepharose beads (GE Healthcare).
Biotin labeling of IL-6R was performed using NHS–ss–
biotin (Pierce) according to manufacturer’s instructions.
The resultant mixture was dialyzed extensively against
buﬀer to remove the free biotin molecules. Protein con-
centration was estimated by SDS–PAGE using known
concentration of IL-6R.
In vitro affinity selection
Three diﬀerent templates for cDNA display, the B domain
of protein A (BDA), Pou-speciﬁc DNA binding domain of
Oct-1 (PDO) were prepared for test screenings by the use
of human immunoglobulin G (IgG) and dsDNA contain-
ing the Pou binding site (Oct-DNA), respectively.
A cDNA library containing BDA/PDO (1:1, 1:3 and
1:20) was prepared by translation of the linker-conjugated
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salt, RT, PvuII digestion and Ni–NTA puriﬁcation via
the 6  His tag. The puriﬁed fractions of BDA/PDO
libraries were added to either IgG-coated beads or to
Oct-DNA-coated beads (20ml of 50% slurry rinsed with
selection buﬀer), respectively, in 100ml of the selection
buﬀer (50mM Tris–HCl pH 7.6, 1mM EDTA, 500mM
NaCl, 0.1% Tween 20) at room temperature for 30min
with rotation. The mixture was incubated at room tem-
perature for 30min with rotation. The beads were then
recovered and washed several times with 500ml of the
selection buﬀer. The bound cDNA display molecules
were removed from the beads with 100ml of elution
buﬀer [0.1M Glycine-HCl (pH 2.5)] and neutralized imme-
diately with 1M Tris–HCl (pH 8.0). The supernatant was
precipitated with ethanol and coprecipitant (Quick-precip
Plus, Edge BioSystems) and dissolved in 10ml of water. An
aliquot of 2ml was ampliﬁed by PCR using 0.2mM of the
primers 50-(FITC) –CAACAACATTACATTTTACATT
CTACAACTACAAGCCACC-30 and 50-TTTCCCCGC
CGCCCCCCGTCCTGCTTCCGCCGTGATGATGAT
GATGATGGCTGCCTCCCCC-30 for 25 cycles con-
sisting of denaturation for 20s, annealing for 15s and
elongation for 30s and then quantitatively analyzed by
denaturing gel electrophoresis (4.5% T and 8M urea)
and ﬂuoroimager.
In order to validate the ratios between the selected PDO
and/or BDA from a mixed pool against a given target, the
selected DNAs were ampliﬁed for various cycles such as
15, 20, 25, 30 and 35 using the cycle conditions as men-
tioned above. We found that a linear range was achieved
around 25 cycles and the linearity started to diminish
around 30 cycles. Thus, we ﬁxed the PCR cycles to 25.
In the case of FLAG-tag, aﬃnity selection was per-
formed using anti-FLAG M2 antibody-agarose beads
(Sigma) for three rounds. PCR products of selected mole-
cules from each round were analyzed by direct sequencing.
The PCR products were also cloned into the TA vector
(Qiagen) and clones were picked randomly for sequencing.
Selection of random library against IL-6R
A random library was prepared by overlap PCR of the
fragments containing the randomized bases that encode
35 residues and essential components for the display of
peptides such as 6 -His and Y-tag at the 30-terminus
and T7 promoter, 50 UTR, Kozak and start codon at
the 50-terminus. Two hundred picomoles of initial library
mRNA was linked to the puromycin linker and translated
into 1ml of lysate for 20min at 308C. Formation of pro-
tein fusions was achieved by the addition of 750mM and
63mM of KCl and MgCl2, respectively. The successive
steps (RT, PvuII digestion and Ni–NTA puriﬁcation)
were scaled up using the pilot conditions as mentioned
earlier. DTT was excluded from all the buﬀers used.
The puriﬁed cDNA display peptides were estimated by
the ﬂuorescence intensity using known FITC-labeled
oligonucleotides.
The ﬁrst round of selection contained 2.7 10
11 library
molecules and 25nM biotinylated IL-6R in S-buﬀer
(50mM Tris–HCl, 500mM NaCl, 1mM EDTA, 0.1%
Tween, pH 7.6, 0.1mg/ml BSA) and incubated for 1h
at room temperature. The mixture was then captured
with 0.2mg streptavidin (SA) beads and washed several
times with S-buﬀer. The bound molecules were recovered
by incubation with 100mM DTT (Sigma) for 10min, pur-
iﬁed and processed to next round.
From round 4 (R4), random mutagenesis was intro-
duced during the PCR ampliﬁcation step of the selected
molecules using the Diversify PCR Random Mutagenesis
Kit (Clontech, CA, USA) designated as Scheme 1.
Mutations were introduced at 3.2–7.3%. Selections were
performed for nine rounds using these conditions
(i.e. upto R12). In Scheme 2, after random mutagenesis,
we performed solid-phase refolding of peptides in the pres-
ence of 1mM oxidized glutathione (Sigma), 10mM
reduced glutathione (Sigma) and protein disulﬁde isomer-
ase (PDI; Takara) added at 1:1 molar ratio with the
protein for 1h at room temperature. The beads were
washed and the peptides were released from the beads
by PvuII digestion and puriﬁed on Ni–NTA resin chro-
matography. Selections were performed for six rounds
using these conditions (i.e. upto R9).
Peptide synthesis
Peptides containing two cysteine residues (Cys-2 type)
composed of one disulﬁde bond and those containing
four cysteine residues (Cys-4 type) composed of two dis-
ulﬁde bonds between C1 and C4, and C2 and C3 were
prepared by the chemical synthesis. Additionally,
Cys4-2B that was composed of a diﬀerent disulﬁde pattern
(i.e. C1 and C3, and C2 and C4) was also synthesized. In
general, a biotin moiety was attached at the N-terminus.
The Cys-2 peptides containing two Cys residues were
custom synthesized by Toray (Tokyo, Japan) and the
Cys4 peptides containing four Cys residues were synthe-
sized and characterized by HPLC proﬁles for their topol-
ogies using retention time by Peptide Institute (Osaka,
Japan) according to the previously reported method (18).
Binding assay
Binding assay of peptides. One mM of synthesized bio-
tinylated peptides were incubated with 200nM of immo-
bilized IL-6R for 1h at room temperature in phosphate
buﬀered saline (PBS). The mixture was centrifuged and
supernatant was discarded. The beads were washed thor-
oughly with PBS-T (Tween 20, 0.1%) and incubated
with streptavidin–horseradish peroxidase (SA-HRP; GE
Healthcare) at 1/2000 dilution for 30min. After several
washings with PBS-T, 200ml of TMB substrate was
added. The reaction was stopped with 0.5M H2SO4
after proper color development. Absorbance was moni-
tored at 450nm.
Determination of dissociation constant (Kd). Binding aﬃn-
ity of the synthesized biotinylated peptides was assayed
according to the previously reported method with a few
modiﬁcations (19). A constant amount of peptide (10nM)
was incubated with varying amounts of IL-6R (1nM to
1mM) in PBS at 258C for 1h. The mixture was applied to a
constant amount of IL-6R-coated beads (200nM) and
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PBS-T, SA-HRP at 1/2000 dilution was added and incu-
bated for 30min. The supernatant was removed and the
beads were washed four to ﬁve times with PBS-T. Two
hundred microliter of the TMB substrate was added for
color development and the reaction was stopped with
0.5M H2SO4. Absorbance was monitored at 450nm.
Data were plotted using GraphPad Prism 4 (GraphPad
software Inc., San Diego, CA, USA).
RESULTS
Characteristics of a puromycin–linker DNA construct,
which facilitates the efficient synthesis of mRNA/
cDNA–protein fusion products
The puromycin–linker DNA (Figure 1A) has four main
characteristics that facilitate the eﬃcient synthesis of
stable mRNA/cDNA–protein fusion molecules. First, a
‘ligation site’ to prepare the mRNA–puromycin conju-
gates that consists of a complementary region that hybri-
dizes with the 30-terminal end of the mRNA template and
a ligation site that promotes an eﬃcient T4 RNA ligase
reaction.
Second, it consists of a ‘biotin site’ for introducing
solid-phase handling of the displayed products. Rapid
puriﬁcation of the mRNA–protein fusion products from
the cell-free translation mixture is a prerequisite for the
subsequent post-translation reactions and the screening
steps. For this purpose, we incorporated a biotin site
into the puromycin–linker DNA (Figure 1A).
Third, it consists of a ‘RT primer site’ for eﬃcient and
rapid conversion of a labile mRNA–protein fusion to a
stable cDNA–protein fusion. With other display techni-
ques, a DNA primer is added to the RT reaction that is
heated to 808C (or more) for several minutes in order
to anneal to the mRNA and initiate the reaction. This
process may denature the protein moiety of the mRNA–
protein fusion molecule. We therefore included a primer
region in our novel puromycin–linker DNA (Figure 1A)
and omitted the heating step prior to the RT reaction. As
a result, more than 90% of the cDNA was found to be
synthesized within 5min from the start of RT reaction
without the initial heating step (Figure 2A). On the
other hand, 60-min incubation was required to synthesize
the cDNA in the conventional RT reaction using RT
primer (50-biotin-TTTCCCCGCCGCCCCCCGTC-30)
without the annealing step (Figure 2B).
Fourth, a ‘restriction enzyme site’ analysis for the
release of the products after all the processing steps is
performed. For this purpose, we incorporated a restriction
enzyme site into the puromycin–linker DNA construct
(Figure 1A). To conﬁrm this, we examined the eﬃciency
of digestion of the linker DNA construct immobilized
on streptavidin-coated beads by the restriction enzyme
PvuII and compared it with the digestion of a free linker
(i.e. liquid phase). Equal amount of ligation product was
reverse transcribed in the liquid-phase and solid-phase (i.e.
onto the bead surface) modes, respectively. Following this,
the product (mRNA/cDNA–puromycin–linker DNA) was
treated by PvuII and the RNA region of product was
degraded by RNase H successively for PAGE analysis
(Figure 3A). As shown in Figure 3B, the eﬃciency of
cleavage of fragment (ii) from fragment (i) in the liquid-
phase mode is about 70% or more (lane 2). Nevertheless,
for the solid-phase mode, where substrate is attached onto
the surface, it is important to assess whether the eﬀect
of steric hindrance between the attached moiety (i.e.
mRNA/cDNA/protein) and bead surface can inﬂuence
the digestion reaction of PvuII, as the restriction site is
close to the bead surface. The eﬃciency of RT and
PvuII digestion to release RT product from the surface
using the solid-phase reaction (lane 3) was comparable
to that of the liquid-phase reaction (lower bands in lanes
2 and 3) and indicates that the beads do not cause any
steric hindrance in the restriction cleavage of the DNA
substrate.
Prior to the solid-phase performance of the puromycin–
linker, we investigated the eﬃciency of the linker in the
liquid phase. In general, 5–20% of the input mRNA tem-
plate was observed to be converted to the mRNA–protein
fusion product within the lysate (Figure 4A). The ﬁnal
yield was 0.1–0.3% after subjecting the templates to
steps shown in Figure 1B (except that the templates were
translated and fusion formation was in the liquid phase).
The scheme of optimization and procedures to convert
mRNA display to cDNA display by the solid-phase pro-
cess is described in Figure 1B. After performing all the
steps, we found that around 0.2% of the puriﬁed
cDNA–protein fusion could be obtained based on the
input mRNA–linker (Figure 4B).
Enrichment efficiency of affinity selection by cDNA display
To examine the performance of our new cDNA display
method in the selection of a target molecule, we con-
structed two diﬀerent DNA templates (Figure 5A). The
B domain of protein A (BDA, 58 residues) (15) and the
POU-speciﬁc DNA-binding domain of Oct-1 (PDO, 74
residues) (16) consist of three and four a-helical structures,
respectively, and do not contain any disulﬁde bonds. The
interaction between each pair, BDA/IgG and PDO/Oct-
DNA is highly speciﬁc and could thus be speciﬁcally
selected from a mixed pool.
The validity of our method was evaluated by designing
a semiquantitative estimation of ratios between the
selected PDO and BDA from a mixed pool against a
given target (Figure 5B). Because puromycin-conjugated
BDA and PDO interacts with IgG and Oct-DNA with
dissociation constants of 13nM (20) and 0.15nM (21),
we attempted to perform a selection against IgG from
a pool comprising cDNA displayed PDO or BDA.
Screening at an equimolar ratio of PDO and BDA
(starting template concentrations) against Oct-DNA
resulted in selection of  20-fold more PDO molecules
than BDA in a single round of selection. Similarly,
screening against IgG yielded a 20-fold higher selected
BDA compared to PDO [Figure 5C(a)]. In addition,
screenings against IgG from pools of PDO and BDA
in the ratio of 3:1 and 20:1, respectively, resulted
in the selection of PDO and BDA in the ratios 1:7
and 1:1 that further conﬁrms this selection eﬃciency
PAGE 5 OF 13 Nucleic Acids Research, 2009,Vol.37, No. 16 e108Figure 1. Schematic diagram of the puromycin–linker DNA construct and its utilities for selection. (A) The puromycin–linker DNA comprises four
parts: a ligation site for mRNA, a primer region for RT, a biotin moiety for immobilization of mRNA–puromycin–linker conjugate to a solid surface
using biotin–streptavidin chemistry and a restriction site for a release of the molecules from the solid surfaces. In addition, the linker has puromycin
(for covalent linking of the expressed protein to mRNA) and FITC (for detection and quantiﬁcation) moieties. (B) Schematic representation of
the cDNA display method using the puromycin–linker DNA. After mRNA is ligated with the puromycin–linker DNA using T4 RNA ligase (a, b),
the resulting product is immobilized on a streptavidin-coated surface (c). The immobilized mRNA is then translated in a cell-free system (d). The
synthesized protein then fuses to its encoding gene via the puromycin moiety (e), and the immobilized mRNA is reverse transcribed using the primer
region of the puromycin–linker DNA (f). A complete mRNA/cDNA–protein fusion product (cDNA display) is then displayed on the solid surface
and proteins can be modiﬁed by post-translation reactions (g). The cDNA display molecule is released from its solid surface by cleavage with the
PvuII enzyme (h) and can be puriﬁed via a C-terminal tag. To conﬁrm the presence of cDNA–protein fusions, the mRNA is digested with RNase
H (i). The outlined steps a, f, g, h are marked as key steps in order to convert mRNA display to cDNA display.
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are selected in a speciﬁc manner against IgG with a
20-fold higher eﬃciency than non-speciﬁc templates
(i.e. PDO).
To further conﬁrm the screening feasibility of our
cDNA display method for another target, we performed
a FLAG-tag selection against the anti-FLAG M2 anti-
body. A random DNA library and FLAG epitope
Figure 3. Solid-phase utilities of the puromycin–linker DNA. (A) Eﬃciency of release of the puromycin–linker DNA from the biotin moiety by
PvuII cleavage. Schematic diagram of experiments to compare the eﬃciency of PvuII cleavage reaction in ‘liquid phase’ versus ‘solid phase’ approaches.
Anequalamountoftheligatedproducts(mRNA–puromycin)werereversetranscribedintheliquidphaseandonmagneticbead,respectively.RTproducts
were then released from the biotin moiety by PvuII cleavage and from the mRNA portion by RNase H (20U; 378C, 20min). (B) Eﬃciency of digestion
by PvuII in the liquid phase (lane 2) and the solid phase (lane 3) was evaluated by 6% PAGE containing 8M urea and detected by FITC ﬂuorescence.
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Figure 2. Characteristics of a novel puromycin–linker DNA: Reverse transcription (RT). Eﬃciency of RT was evaluated by comparison of the
puromycin–linker DNA (A) versus a biotinylated primer (B). The BDA mRNA (334bp) was ligated to the puromycin–linker and RT reactions were
performed at 428C for either 5min or 20min. After RT, the reverse transcribed single-stranded cDNA fused linker DNA–mRNA was analyzed by
denaturing PAGE (6% T gel containing 8M urea) and detected using FITC ﬂuorescence (A). To compare these results with conventional RT (used
in case of mRNA display), the same mRNA (334 b) (without the linker) was reverse transcribed after the addition of a biotinylated primer at room
temperature for either 5min or 60min. All products were incubated at 708C for 15min to inactivate the reverse transcriptase. In order to resolve the
reverse transcribed cDNA product from the mRNA template in conventional RT, the reaction was followed by incubation with streptavidin (SA)
for 30min as described (29) and the cDNA products attached to streptavidin (SA) were analyzed by denaturing PAGE (4% gel containing 8M urea)
and detected with SYBR Gold dye (B).
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structed as shown in Figure 5D(a). By using the initial
library comprising 99.9% random DNA sequences and
0.1% FLAG DNA template, we examined whether the
FLAG DNA template could be successfully ampliﬁed
after several rounds of selection. The selected library
pool after each round was analyzed by direct sequencing
of the PCR products, and a convergence on the
FLAG epitope-like sequence was evident after the third
round of selection [Figure 5D(b)]. We also found
that 17% of the total selected clones harbored the
FLAG-encoded sequence in the third round, up from
0.1% at the start of the screening. These results indicate
that cDNA display is indeed a useful and suitable method
for the aﬃnity selection of ligand peptides and functional
proteins.
Selection of multiple disulfide bond containing molecules
from a random library
To evaluate the potential performance of the method, we
carried out selections using a 32-residue random library
against IL-6R. We were interested in isolating peptides
that were rich in cysteine residues and bonded by intra-
molecular disulﬁde bonds. For this purpose, we placed a
ﬁxed cysteine residue that preceded the 32 random resi-
dues with the expectation that cysteine residue(s) from
the random region would be disulﬁde bonded with the
ﬁxed cysteine residue and selected. Aﬃnity selection was
carried out from rounds 1–3 (R1-R3) (see ‘Selection of
random library against IL-6R’ section). After this, two
selection schemes were designed (Figure 6A). In the ﬁrst
scheme, from R4 random, mutagenesis was performed
during the PCR ampliﬁcation (mRNA display-like proce-
dure), while in the second scheme, from R4, in addition to
mutagenesis, ‘on-beads’-post-translational modiﬁcations
were introduced before selection such as refolding in the
presence of protein disulﬁde isomerase (PDI) (cDNA dis-
play-like procedure). After selection, both of the pools
were cloned and sequenced.
The initial random library contained 32 random residues
ﬂanked by a ﬁxed cysteine residue at the N-terminal and
G3S, 6 -His and G2S at the C-terminal (Figure 6B). The
selection using Scheme 1 enriched Cys-2-like sequences (12
out of 12 clones) after 12 rounds of selection, in which the
two cysteine residues (i.e. one ﬁxed cysteine residue and the
second residue from the random region) were expected to
be linked by one disulﬁde bond. In Scheme 2, the enriched
sequences contained a mixture of Cys-2- and Cys-4-like
sequences at 50% each (6 clones of each type out of the
total 12 clones) after nine rounds of selection, in which two
and four cysteine residues (i.e. one ﬁxed cysteine residue
and the other residues from the random region) were
linked by one and two disulﬁde bonds. After R7, 30% of
Cys-4 sequences were found among the selected clones
compared to 50% at R9 that indicate that Cys-4 sequences
were enriched over Cys-2 sequences (data not shown).
Point mutations were observed within the sequences
and could not be assigned to any group as no two
sequences were identical (Figure 6B). Some of the selected
candidates, from each selection scheme, containing two
and four cysteine residues were chemically synthesized
and were found to bind to IL-6R in the nanomolar range
(4–100nM; Table 1).
Due to the presence of four cysteine residues in Cys-4
peptides, various permutations were possible for the dis-
ulﬁde bond formation. To investigate the correct pairs
of cysteine residues involved in the formation of disulﬁde
bonds, we synthesized two diﬀerent types of molecules
(Cys4-2-A and Cys4-2-B) as shown in Figure 7A. In
Cys4-2-A, disulﬁde bonds were formed between C1 and
C4 and C2 and C3, while in Cys4-2-B, disulﬁde bonds
were between C1 and C3 and C2 and C4, respectively.
The two molecules were subjected to in vitro binding
analysis for IL-6R. Indeed, we found that the pattern of
disulﬁde bonds is important for the proper function.
Cys4-2-A binds strongly to IL-6R, but Cys4-2-B did not
show any apparent aﬃnity (Figure 7B).
Figure 4. Eﬃciency of the formation of mRNA– and cDNA–protein
fusion. (A) Synthesis of BDA mRNA–protein fusion in the liquid
phase. mRNA–puromycin–linker with FITC (lane 1) was translated
with a cell-free translation system followed by the addition of a high-
salt solution (KCl and MgCl2 to ﬁnal concentrations of 750 and
63mM, respectively) to the lysate to facilitate the formation of fusions
via puromycin (lane 2) and evaluated by 6% SDS–PAGE containing
8M urea and detected by FITC ﬂuorescence. The eﬃciency of the
fusion formation was calculated by using the following equation: %
eﬃciency=a/a+b 100, where a is the band representing mRNA–
linker–protein (upper band) and b represents mRNA–linker (lower
band). (B) Synthesis of cDNA–protein fusion in the solid phase.
BDA mRNA–puromycin–linker with FITC was immobilized on strep-
tavidin beads followed by steps (d–i) as shown in Figure 1B. Lane 1,
product after performing all the steps and digestion by RNase H
(for detection of cDNA–linker and cDNA–linker–protein); lane 2, ﬂow-
through of the 6 -His puriﬁcation process by Ni–NTA resin chroma-
tography followed by RNase H treatment, and lane 3, eluate of the
6 -His puriﬁcation process digested by RNase H. Amount in lanes 2
and 3 have been adjusted to contain 50 times the amount that was
loaded in lane 1. The samples were evaluated by 6% SDS–PAGE con-
taining 8M urea and detected by FITC ﬂuorescence. The eﬃciency of
the formation of the ﬁnal cDNA–linker protein was calculated based
on the input template concentration (not shown here) in two steps.
First, we calculated the eﬃciency of the formation of mRNA–linker–
protein fusion using mRNA–linker templates (explained above).
Second, we compared the intensities of the fusion bands (upper band)
by taking into account the folds of cDNA–linker loaded (in this case
50). Therefore, % eﬃciency of formation of cDNA–linker–protein
(Z)=c/d fcDNA, where c is the mRNA–linker–protein, d is the
cDNA–linker–protein and is folds of cDNA–linker loaded. The ﬁnal
eﬃciency of the formation of cDNA was calculated using the following
equation:% eﬃciency=[a/(a+b)  100]/Z.
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Although it has been 10 years since the development of the
in vitro virus and mRNA display (5,6), these techniques
have not yet found common usage compared to the phage
display (1). One of the reasons is the diﬃculty in preparing
mRNA–puromycin conjugates (template) for translation
in the mRNA–protein fusion reaction. Previously, large
amounts of high-cost puromycin–linker DNA (at about
a 200-fold molar excess over the input mRNA) were
required because the eﬃciency of the ligation reaction
was low due to the absence of hybridization between
mRNA and the puromycin–linker (22). To overcome
this problem, two methods have been previously reported:
splint ligation and photo-crosslinked ligation. Using a
splint oligo in order to reduce the ligation reaction time
and excess amounts of puromycin–linker DNA, however,
requires a quite cumbersome denaturing gel puriﬁcation
step to separate the splint-oligo DNA from the ligated
mRNA template and this necessarily leads to the reduced
recovery of the ligated product (23). The mRNA–puromy-
cin conjugation by psoralen photo-crosslinking is rapid
and eﬃcient; however, mRNA degradation can occur as
a result of the UV irradiation step during the process (24).
On the other hand, ligation of mRNA and puromycin–
linker by utilizing ‘Y-ligation method’ that involves
T4 RNA ligase (25) is extremely fast under moderate
conditions (258C,  1h) and thus avoids any damage to
the mRNA by UV.
Another important aspect of mRNA display is its sta-
bility. A simple solution to improve stability is to convert
the mRNA portion to a cDNA. Thus, the concept of
cDNA–protein fusions has been previously proposed
(12,13). In general, to perform in vitro protein selection
using a cell-free translation system, double strand forma-
tion (i.e. mRNA/cDNA–protein fusion) would be impor-
tant not only for the stabilization of the fusion molecule
but also in order to restrict any unexpected interactions
of the mRNA, which often binds to various kinds of bio-
logical molecules as aptamers or complementary oligonu-
cleotides. However, it is very diﬃcult to perform RT in a
cell-free translation mixture because ribosomes are
still bound to the mRNA and can disrupt the synthesis
of the cDNA. We found that a combination of a rapid
puriﬁcation with streptavidin-coated magnetic beads
under moderate conditions, buﬀer exchange and a rapid
on-beads RT were very suitable for this purpose and
Figure 5. Validation of the cDNA display method by aﬃnity selection
experiments of proteins without disulﬁde bonds. (A) DNA template
constructs used in the test screening experiments encoding the Pou-
speciﬁc DNA-binding domain of Oct-1 (PDO) (top) or the B domain
of protein A (BDA) (bottom).  is the 50 untranslated region of
tobacco mosaic virus and the HR region is a complementary puromy-
cin–linker DNA sequence. (B) Selection scheme using cDNA display.
PDO or BDA were used as templates to generate mRNA/cDNA–pro-
tein fusion products (cDNA display molecules) following the steps of
transcription, ligation of mRNA to puromycin–linker, immobilization
on streptavidin-coated beads, translation, fusion formation with
mRNA, reverse transcription, restriction digestion and puriﬁcation
via 6 -His. The cDNA displayed mixture of both molecules was sub-
jected to aﬃnity selection against either Oct-DNA or IgG. The cDNA
moieties of the selected molecules were then ampliﬁed by PCR from the
eluted fraction after several washes and then analyzed by 8M urea-
denatured 5% PAGE. Selection against IgG enriches BDA (lower red
band), while selection against Oct-DNA enriches PDO (upper black
band). (C) The results of the aﬃnity selection by the Oct-DNA or
IgG. The initial molar ratio of PDO and BDA in the cDNA-display
binary mixtures was 1:1 (a), 3:1 or 20:1 (b). After a single aﬃnity
selection against the given targets, the PCR products of the cDNA
display molecules ‘before’ and ‘after’ selection were analyzed by 8M
urea-denatured 4.5% PAGE. The PDO and BDA are shown by arrows.
(D) Model experiment of aﬃnity selection of FLAG epitope by an anti-
FLAG antibody. (a) The DNA encoding randomized 10 amino-acid
residues and FLAG epitope (DYKDDDDK) were prepared as
described in ‘vectors, oligonucleotides and library construction’. The
initial DNA library comprised a mixture of 1 pmol ‘random’ DNA
templates and 1 fmol ‘FLAG’ DNA templates. Thus, the initial
random peptide library contained 0.1% FLAG epitope. (b) Direct
sequencing of the PCR products from the initial library and from the
third round of aﬃnity selection by a FLAG antibody.
PAGE 9 OF 13 Nucleic Acids Research, 2009,Vol.37, No. 16 e108Figure 6. Selection of IL-6R binding molecules from a random library. (A) Selection schemes for the enrichment of disulﬁde bond-containing
molecules. The initial library was subjected to aﬃnity selection for three rounds (R1–R3). In Scheme 1 (mRNA display-like procedure), from R4
onward, random mutagenesis was introduced in the PCR ampliﬁcation step of the R3 selected molecules followed by selection upto R12. In
Scheme 2 (cDNA display-like procedure), in addition to random mutagenesis, post-translational modiﬁcations were also introduced and the peptides
were allowed to fold in the presence of protein disulﬁde isomerase (PDI) and redox conditions followed by selection upto R9. The displayed peptides
were puriﬁed owing to the ease of buﬀer exchange in solid-phase handling. The enriched pools from both the schemes were cloned and sequenced.
(B) Library construction and sequence characteristics of the selected molecules. A random library was constructed containing 32 residues (shown by
X), a ﬁxed cysteine at the N-terminus and 6 -His at the C-terminus for the puriﬁcation of the peptides. The library was subjected to aﬃnity selection
using the two schemes described in (A). Selection with Scheme 1 generated molecules containing two cysteine residues (denoted as Cys-2)—one ﬁxed
cysteine and the second from the random region (shown in red). The consensus sequence is shown as S1-Cys2-con and point mutations are
highlighted in white. In Scheme 2, molecules containing two (Cys-2; top) and four cysteine residues (Cys-4; bottom) were enriched. S2-Cys2-con
and S2-Cys4-con are the consensus sequences of Cys2 and Cys4 peptides, respectively. Point mutations are highlighted in white.
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pared to 30–60min in the previous reports (12,13)
(Figure 2). In this regard, the magnetic bead separation
method by biotin–streptavidin chemistry is highly suitable
in comparison with the oligo(dT) puriﬁcation method that
demands the undesirable elution conditions (the low salt
buﬀer and high temperature) causing severe damage to the
protein components. In our method, after RT, the subse-
quent release of immobilized cDNA fusion from the strep-
tavidin beads by PvuII digestion is carried out at 378C that
is physiologically favorable and highly eﬃcient (Figure 3).
In general, PvuII cleaves only dsDNA of the linker DNA
portion, but not of the mRNA/cDNA portion including
random region. Thus, the diversity of a random library is
not aﬀected by the digestion reaction.
The performance of cDNA display in model experi-
ments using ligand proteins was evaluated and found
to be comparable to or better than the other methods
(Figure 5). Therefore, we investigated the performance
of our method in generating disulﬁde bond containing
peptides from a random library as discussed below.
In the last decade, a minimizing antibody by rearran-
ging antibody fragments (e.g. scFv) has been developed
to overcome some problems of antibodies for clinical ther-
apeutics. Recently, various kinds of scaﬀold derived from
non-immunoglobulin proteins have been shown to be
useful as alternatives of antibodies. In particular, these
proteins oﬀer smaller size for production and clinical eﬀec-
tiveness (26). Peptide scaﬀolds such as Kunitz domains,
scorpion toxins, knottins and peptide aptamers are attrac-
tive for the development of lead molecules as drugs
because of their small size ( 40 residues) that can be
synthesized and modiﬁed chemically. These peptide
scaﬀolds have two or three disulﬁde bonds to stabilize
Figure 7. Possibilities of disulﬁde bond formation and the activity of the peptides. (A) Two possibilities out of various permutations for the disulﬁde
bond formation were designed and tested. Cys4-2-A denotes clone 2 of S2-Cys4 series containing Type-A disulﬁde bond pattern i.e. C1 and C4, C2
and C3, while Cys4-2-B denotes clone 2 with disulﬁde pattern i.e. C1 and C3, C2 and C4. The schematic structures are shown on the right.
(B) Biochemical binding assay. An in vitro biochemical assay based on was designed as shown in the schematic on the right-hand side. The
biotinylated peptides were allowed to bind to IL-6R followed by binding of SA-HRP and detection with the addition of substrate. Non-coated
beads denote beads without IL-6R. Cys4-2-A was found to bind to IL-6R and Cys4-2-B could not bind (also shown in the schematic on the right-
hand side).
Table 1. Characteristics of the selected peptides
Peptides
a Sequence
b Selection scheme Disulﬁde bonds
c Kd (nM)
d
S1-Cys2-Con CYPFVIAVHFSPGHSLRYPASYCNDASVSTLFIGTY –– –
Sl-Cys2-1 CYPVVIAVHFSPGHSLRYPGSYCNDTSGSTLFIGTY 1 1 (C1-C2) 12 1.4
Sl-Cys2-6 CYPFVIAVHFSPGHSLRYPASYCNDASASTLFIGTY 1 1 (C1-C2) 4 0.6
Sl-Cys2-ll CYPLVIAVHFSPGHSLRYPVSYCNDTSVSTLFIGTY 1 1 (C1-C2) 100 9
S2-Cys4-Con CHSTFVGTLCFVALGEYPTLCYYAFVDRCASTEEGN –– –
S2-Cys4-2 CHSTFVGTLCFVALGEYPTLCYDTFVDRCASTEEGN 2 2 (C1-C4, G2-C3) 55 3.7
S2-Cys4-3 CHSTFVGTLCFVALGEYPTLCYYAFVDRCASTEEGG 2 2 (C1-C4, C2-G3) 100 12.5
aS1-Cys2-Con, and S2-Cys4-Con, are the consensus sequences of Cys2 and Cys4 candidates, respectively.
bSequences of the random region (32 residues) are shown. Point mutations are indicated in bold. Cysteine residues are underlined.
cDisulﬁde bonds between the cysteine residues are indicated and were obtained by chemical synthesis. The importance of disulﬁde bonds for activity
of the peptides was also investigated by preparing DTT reduced samples.
dThese values were measured by Enzyme Linked Immuno Soibant Assay (ELISA; see Materials and Methods section).
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are performed for disulﬁde bond-containing peptide scaf-
fold library by mRNA display, it may be diﬃcult and
impractical to display such proteins and/or libraries.
Furthermore, refolding of proteins is also impractical as
methods such as dialysis are tedious, time consuming and
lead to low recovery of proteins. On the other hand, we
have found that the foldability of the proteins synthesized
on the solid surface using a cell-free translation system is
increased with our method (14). Furthermore, proteins
that are diﬃcult to express can be displayed by combining
solid-phase synthesis, easy buﬀer exchange and refolding
using the puromycin–linker, which is the most important
point. Based on solid-phase handling and selection from a
32-residue random library against IL-6R facilitated by
cDNA display (Scheme 2 in Figure 6), we isolated peptides
containing two disulﬁde bonds that were found to have
a speciﬁc disulﬁde pattern for their activity (Figures 6
and 7 and Table 1). In addition, peptides containing a
single disulﬁde bond could also be selected as in the case
of mRNA display-like procedure (Scheme 1 in Figure 6;
Table 1). Selection of peptides from a random library
containing single disulﬁde bond have been reported (28);
however, there are no published reports regarding selected
peptides containing more than one disulﬁde bond.
Therefore, this is the ﬁrst report to select peptides contain-
ing two disulﬁde bonds from a random library by in vitro
protein selection using cell-free translation. We believe
that this will open up the new horizon to screen various
kinds of functional proteins, which demands disulﬁde
shuﬄing. Thus, cDNA display is becoming a far more
eﬃcient technique for functional protein screening com-
pared to other reported display methods involving a
liquid-phase approach.
In conclusion, novel and sophisticated cDNA display
methods that make use of novel linkers such as ours will
provide valuable new tools and solutions for the easier
and more eﬃcient in vitro selection of functional proteins
using cell-free translation systems (Figure 1). This will also
allow the use of various selection conditions with rapid,
robust and stable mRNA/cDNA–protein fusions.
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